Published in PharmTech
Authors: Craig A. Steger, Thomas J. Joyce, and Oded Ben-Joseph
Outcome Capital has been following the pharma services market dynamics for the past 5 years. The authors believe that this fragmented segment will give way to greater consolidation by both financial buyers looking to roll up smaller players and larger contract research organizations seeking to expand into value-added specialty service areas. Adding to this consolidation is a tepid fund-raising environment, opening the door for financial buyers to play a role in consolidating many niche players.
BOSTON–(BUSINESS WIRE)–Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that ELIOS Vision, Inc. completed a growth financing round to support its European commercialization. Outcome Capital served as the exclusive strategic and financial advisor to the company. ELIOS’ implant-free, minimally invasive Excimer Laser Trabeculostomy glaucoma procedure is approved […]Read More
Outcome Capital Life Science Market Pulse May 2022 Click to view our LifeSciences Pulse NewsletterDownload